CPT® Code 81413

Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia); genomic sequence analysis panel, must include sequencing of at least 10 genes, including ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A

The CPT® Code 81413 pertains to a genomic sequence analysis panel specifically designed to identify mutations associated with cardiac ion channelopathies, which include conditions such as Brugada syndrome, long QT syndrome, short QT syndrome, and catecholaminergic polymorphic ventricular tachycardia (CPVT). These ion channelopathies can lead to serious cardiac issues, including arrhythmias and sudden cardiac arrest, often triggered by specific stimuli, despite the absence of structural heart anomalies. The analysis must encompass the sequencing of at least ten genes, which are critical in the functioning of ion channels in the heart. Among these genes are ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A. The SCN5A gene, in particular, is known for its role in encoding sodium channels within cardiac muscle, and mutations in this gene are closely linked to Brugada syndrome, which can manifest as syncope or sudden death, particularly during rest or sleep. Triggers for these events may include fever or large meals. CPVT is characterized by a unique bi-directional arrhythmia that is often provoked by physical exertion or emotional stress. In the case of long QT syndrome, a significant majority of gene mutations (approximately 80-90%) are found in the SCN5A, KCNQ1, and KCNH2 genes, which are responsible for potassium ion channels that play a vital role in cardiac, nerve, and immune cell function. Short QT syndrome is similarly influenced by disturbances in potassium ion channels. Additionally, mutations affecting calcium ion channels can be identified in the RYR2 and CASQ2 genes. Other genes such as ANK2, CAV3, KCNE1, and KCNE2 may also contribute to the disruption of sodium, potassium, or calcium ion channels in the heart. Genetic testing through this genomic sequence analysis is essential for confirming diagnoses, providing risk stratification for symptomatic patients, identifying at-risk family members or silent carriers, guiding treatment strategies, and facilitating genetic counseling. The testing process involves obtaining a blood sample through venipuncture, which is reported separately. The analysis utilizes advanced techniques such as chip-based oligonucleotide hybridization and direct sequencing of the protein-coding regions and adjacent areas of the targeted exons for the specified genes.